MRI Recommendations for AQP4-Positive Neuromyelitis Optica Spectrum Disorder and MOG Antibody-Associated Disease
This systematic review presents expert recommendations on MRI protocols for diagnosing and monitoring AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG) antibody disease. It highlights the challenges in MRI interpretation due to overlapping imaging features and suggests standard sequences and timing for MRIs across disease phases.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
These recommendations are important for improving consistency and accuracy in MRI usage for these specific CNS disorders, potentially aiding clinical decision-making.
What this does not prove
The study does not provide evidence for clinical efficacy or specific outcomes from the recommendations, focusing solely on suggested practices for MRI use.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-28
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceUse of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations. ↗DOI: 10.1038/s41582-026-01271-2
Supporting passages (5)
study designIn this Expert Recommendation on behalf of the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) study group, we provide recommendations for the practical use of conventional and non-conventional MRI for diagnosis, monitoring and research in AQP4+ NMOSD and MOGAD.
findingsAquaporin 4-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are antibody-mediated inflammatory disorders of the CNS with distinct immunopathogenic, clinical and imaging profiles.
findingsMRI is fundamental for diagnosis, monitoring and treatment decisions in these disorders, yet challenges persist, including overlap of imaging features, variable lesion evolution and the absence of standardized acquisition protocols.
publication datePublication date: 2026-09-28
limitationsTitle: Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.